Determinants of left ventricular hypertrophy and its progression in high-flux haemodialysis

Blood Purification

Volumn 21, Issue 2, 2003, Pages 163-169

  Kong, Chiew H ^a   Farrington, Ken ^a  

^a LISTER HOSPITAL   (United Kingdom)

Author keywords

Haemodialysis; Hyperparathyroidism; Left ventricular hypertrophy; Risk factors

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RENAL DIALYSIS; RISK FACTORS; WEIGHT GAIN;

EID: 0037221547     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069155     Document Type: Article

References (32)

1. Raine AE: The heart and renal failure. Contrib Nephrol 1994;109:76-83.
2. Amann K, Rychlik I, Miltenberger MG, Ritz E: Left ventricular hypertrophy in renal failure. Kidney Int Suppl 1998;68:S78-S85.
3. Foley RN, Parfrey PS, Harnett JD, et al: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-192.
4. Schunkert H, Dzau VJ, Tank SS, Hirsch AT, Apstein C, Lorell BH: Increased rat angiotensin converting enzyme activity and mRNA levels in pressure overload left ventricular hypertrophy: Effects on coronary resistance, contractility, and relaxation. J Clin Invest 1990;86:1913-1920.
5. Hernandez D, Lacalzada J, Salido E, et al: Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism. Kidney Int 2000;58: 889-897.
6. Osono E, Kurihara S, Hayama N, et al: Insertion/deletion polymorphism in intron 16 of the ACE gene and left ventricular hypertrophy in patients with end-stage renal disease. Am J Kidney Dis 1998;32:725-730.
7. Schmidt A, Kiener HP, Barnas U, et al: Angiotensin-converting enzyme polymorphism in patients with terminal renal failure. J Am Soc Nephrol 1996;7:314-317.
8. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving haemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 2001;12:2759-2767.
9. Devereux RB, Pickering TG, Alderman MH, et al: Left ventricular hypertrophy in hypertension. Prevalence and relationship to pathophysiologic variables. Hypertension 1987;9:II53-II60.
10. Tucker B, Fabbian F, Giles M, et al: Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant 1997;12:724-728.
11. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-354.
12. Krumholz HM, Larson M, Levy D: Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol 1993;72:310-313.
13. Sagie A, Benjamin EJ, Galderisi M, et al: Echocardiographic assessment of left ventricular structure and diastolic filling in elderly subjects with borderline isolated systolic hypertension (the Framingham Heart Study). Am J Cardiol 1993;72:662-665.
14. Cannella G, Paoletti E, Barocci S, et al: Angiotensin-converting enzyme gene polymorphism and reversibility of uremic left ventricular hypertrophy following long-term antihypertensive therapy. Kidney Int 1998;54:618-626.
15. Lins LE, Hedenborg G, Jacobson SH, et al: Blood pressure reduction during hemodialysis correlates to intradialytic changes in plasma volume. Clin Nephrol 1992;37:308-313.
16. Ozkahya M, Ok E, Cirit M, et al: Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant 1998;13:1489-1493.
17. Covic A, Goldsmith DJ, Georgescu G, Venning MC, Ackrill P: Echocardiographic findings in long-term, long-hour hemodialysis patients. Clin Nephrol 1996;45:104-110.
18. McGonigle RJ, Fowler MB, Timmis AB, Weston MJ, Parsons V: Uremic cardiomyopathy: Potential role of vitamin D and parathyroid hormone. Nephron 1984;36:94-100.
19. Lemmila S, Saha H, Virtanen V, Ala-Houhala I, Pasternack A: Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Am J Nephrol 1998; 18:404-410.
20. Park CW, Oh YS, Shin YS, et al: Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999;33:73-81.
21. Sato S, Ohta M, Kawaguchi Y, et al: Effects of parathyroidectomy on left ventricular mass in patients with hyperparathyroidism. Miner Electrolyte Metab 1995;21:67-71.
22. Piovesan A, Molineri N, Casasso F, et al: Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 1999;50:321-328.
23. Stefenelli T, Mayr H, Bergler KJ, et al: Primary hyperparathyroidism: Incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med 1993; 95:197-202.
24. Stefenelli T, Abela C, Frank H, Koller SJ, Niederle B: Time course of regression of left ventricular hypertrophy after successful parathyroidectomy. Surgery 1997;121:157-161.
25. Hui Y, Hao Y, Chen X, Jing S, Dai Z: Relationship between some humoral factors and left ventricular hypertrophy in essential hypertension. Chin Med J (Engl) 1996;109:885-887.
26. Rampe D, Lacerda AE, Dage RC, Brown AM: Parathyroid hormone: An endogenous modulator of cardiac calcium channels. Am J Physiol 1991;261:H1945-H1950.
27. Smogorzewski M, Zayed M, Zhang YB, Roe J, Massry SG: Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol 1993;264:H1998-H2006.
28. van Der Kleij FG, Schmidt A, Navis GJ, Haas M, Yilmaz N, de Jong PE, Mayer G, de Zeeuw D: Angiotensin converting enzyme insertion/deletion polymorphism and short term renal response to ACE-inhibition: Role of sodium status. Kidney Int 1997;53(suppl 2):S23-S26.
29. Ruzicka M, Leenen FH: Relevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy. Circulation 1995;91:16-19.
30. Eckardt KU: Cardiovascular consequences of renal anaemia and erythropoietin therapy. Nephrol Dial Transplant 1999;14:1317-1323.
31. Foley RN, Parfrey PS, Morgan J, et al: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000;58:1325-1335.
32. Whalley GA, Gamble GD, Doughty RN, MacMahon S, Sharpe N: Selection bias in clinical research when subjects are excluded because of failure to estimate left ventricular mass by echocardiography. J Am Soc Echocardiogr 1998;11:1050-1055.